drugset / Trial / NCT06624085
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Timeline
- Start
- 2025-04-28
- Primary completion
- 2030-03-31
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |